Gaxos.ai (NASDAQ:GXAI – Get Free Report) and biote (NASDAQ:BTMD – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.
Profitability
This table compares Gaxos.ai and biote’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gaxos.ai | -64.81% | -38.79% | -36.99% |
| biote | 3.19% | -22.33% | 12.10% |
Insider and Institutional Ownership
42.6% of Gaxos.ai shares are owned by institutional investors. Comparatively, 21.7% of biote shares are owned by institutional investors. 3.2% of Gaxos.ai shares are owned by insiders. Comparatively, 32.4% of biote shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gaxos.ai | 1 | 0 | 0 | 0 | 1.00 |
| biote | 1 | 1 | 1 | 1 | 2.50 |
biote has a consensus price target of $2.50, suggesting a potential upside of 103.25%. Given biote’s stronger consensus rating and higher possible upside, analysts plainly believe biote is more favorable than Gaxos.ai.
Earnings and Valuation
This table compares Gaxos.ai and biote”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gaxos.ai | $6.01 million | 1.07 | -$3.90 million | ($0.50) | -1.19 |
| biote | $183.53 million | 0.24 | $27.05 million | $0.11 | 11.18 |
biote has higher revenue and earnings than Gaxos.ai. Gaxos.ai is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Gaxos.ai has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, biote has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.
Summary
biote beats Gaxos.ai on 13 of the 15 factors compared between the two stocks.
About Gaxos.ai
Gaxos.ai Inc. engages in developing artificial intelligence applications for various sectors. Its portfolio includes applications in mental and physical wellbeing, coaching, and gaming. In addition, it offers Gaxos, a gaming platform develop, design, acquire, and manage conventional games and combine these games with unconventional game mechanisms. The company was formerly known as The NFT Gaming Company, Inc. and changed its name to Gaxos.ai Inc. in January 2024. Gaxos.ai Inc. was incorporated in 2021 and is based in Roseland, New Jersey.
About biote
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.
Receive News & Ratings for Gaxos.ai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gaxos.ai and related companies with MarketBeat.com's FREE daily email newsletter.
